BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ciltacabtagene autoleucel readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ciltacabtagene autoleucel\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05666700-3161@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ciltacabtagene autoleucel: Phase 1 readout est. (NCT05666700)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 1.\nStudy: CAR-T Cell Therapy
  in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo I
 maging and Molecular Monitoring Study\nEstimated primary completion: Janua
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ciltacabtage
 ne-autoleucel#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05666700
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04133636-3161@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Ciltacabtagene autoleucel: Phase 2 readout est. (NCT04133636)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  A Study of JNJ-68284528\, a Chimeric Antigen Receptor T Cell (CAR-T) Ther
 apy Directed Against B-cell Maturation Antigen (BCMA) in Participants With
  Multiple Myeloma\nEstimated primary completion: 26 February 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ciltacabtagene-autoleucel#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT041336
 36
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06623630-3161@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ciltacabtagene autoleucel: Phase 1 readout est. (NCT06623630)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 1\, Multiple Myeloma.\nStudy:
  Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior 
 to Ciltacabtagene Autoleucel (Carvykti\; Cilta-cel) for Multiple Myeloma (
 MM) Patients With Impaired Renal Function\nEstimated primary completion: 3
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ciltacab
 tagene-autoleucel#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06623630
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07093554-3161@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Ciltacabtagene autoleucel: Phase 1 readout est. (NCT07093554)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 1\, Multiple Myeloma.\nStudy:
  Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy
  Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractor
 y Multiple Myeloma\nEstimated primary completion: 1 July 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07093554
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06550895-3161@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270826
DTEND;VALUE=DATE:20270827
SUMMARY:Ciltacabtagene autoleucel: Phase 2 readout est. (NCT06550895)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of
  Participants With High-Risk Multiple Myeloma\nEstimated primary completio
 n: 26 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ci
 ltacabtagene-autoleucel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06550895
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07200089-3161@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20280310
DTEND;VALUE=DATE:20280311
SUMMARY:Ciltacabtagene autoleucel: Phase 1 readout est. (NCT07200089)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 1\, Multiple Myeloma.\nStudy:
  Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Fo
 llowing BCMA CAR-T Therapy (Cilta-cel)\nEstimated primary completion: 10 M
 arch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ciltacabta
 gene-autoleucel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07200089
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07149857-3161@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20280412
DTEND;VALUE=DATE:20280413
SUMMARY:Ciltacabtagene autoleucel: Phase 2 readout est. (NCT07149857)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel\nEst
 imated primary completion: 12 April 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07149857
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07725406-3161@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Ciltacabtagene autoleucel: Phase 1 readout est. (NCT07725406)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 1\, Multiple Myeloma.\nStudy:
  Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Mu
 ltiple Myeloma\nEstimated primary completion: 1 August 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07725406
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04923893-3161@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20290214
DTEND;VALUE=DATE:20290215
SUMMARY:Ciltacabtagene autoleucel: Phase 3 readout est. (NCT04923893)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy:
  A Study of Bortezomib\, Lenalidomide and Dexamethasone (VRd) Followed by 
 Cilta-cel\, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by L
 enalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diag
 nosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy\nEs
 timated primary completion: 14 February 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04923893
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577025-3161@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Ciltacabtagene autoleucel: Phase 2 readout est. (NCT06577025)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  A Study of Different Sequences of Cilta-cel\, Talquetamab in Combination 
 With Daratumumab and Teclistamab in Combination With Daratumumab Following
  Induction With Daratumumab\, Bortezomib\, Lenalidomide and Dexamethasone 
 in Participants With Standard-risk Newly Diagnosed Multiple Myeloma\nEstim
 ated primary completion: 2 September 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06577025
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06940297-3161@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20310815
DTEND;VALUE=DATE:20310816
SUMMARY:Ciltacabtagene autoleucel: Phase 2 readout est. (NCT06940297)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients 
 With Relapsed or Refractory Multiple Myeloma\nEstimated primary completion
 : 15 August 2031. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cil
 tacabtagene-autoleucel#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06940297
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06574126-3161@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20320930
DTEND;VALUE=DATE:20321001
SUMMARY:Ciltacabtagene autoleucel: Phase 2 readout est. (NCT06574126)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma\nEstim
 ated primary completion: 30 September 2032. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06574126
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05257083-3161@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Ciltacabtagene autoleucel: Phase 3 readout est. (NCT05257083)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy:
  A Study of Daratumumab\, Bortezomib\, Lenalidomide and Dexamethasone (DVR
 d) Followed by Ciltacabtagene Autoleucel Versus Daratumumab\, Bortezomib\,
  Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Tr
 ansplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma\nEst
 imated primary completion: June 2033. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05257083
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05201781-3161@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20370729
DTEND;VALUE=DATE:20370730
SUMMARY:Ciltacabtagene autoleucel: Phase 4 readout est. (NCT05201781)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 4\, Multiple Myeloma.\nStudy:
  A Long-term Study for Participants Previously Treated With Ciltacabtagene
  Autoleucel\nEstimated primary completion: 29 July 2037. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05201781
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
